Clinical trials for cancer patients
The Clínica is the private center that promotes the most clinical trials in Spain. We aim to generate knowledge to change the course of diseases.
-
March 31, 2025Pamplona/MadridIn recruitment
LOXO-BTK-20030 Clinical trial of pyrtobrutinib (LOXO-305) compared to ibrutinib in patients with chronic lymphocytic leukemia/small cell lymphocytic lymphoma (BRUIN-CLL-314).
The objectives of this clinical trial are as follows: - To determine the response of CLL/LLCP patients to treatment with pyrtobrutinib (group A) compared to ibrutinib (group B). - Determine the duration of beneficial effects of treatment with the study drugs (including how long patients live). - Determine safety and tolerability in group A and group B. - Determine how patients in group A are doing compared to those in group B. -
March 31, 2025PamplonaIn recruitment
RMC-6236-302 Phase III, multicenter, open-label, randomized, open-label clinical trial to evaluate RMC-6236 in patients with previously treated metastatic pancreatic ductal adenocarcinoma (PDCA).
The purpose of a trial is to collect information about the investigational drug: RMC-6236 -
March 31, 2025Pamplona/MadridIn recruitment
J2N-MC-JZNX Phase II clinical trial to evaluate the efficacy and safety of Pirtobrutinib in participants with leukemia who have previously received treatment with a covalent Bruton's tyrosine kinase inhibitor.
Clinical trial to compare the overall response rate of: - pirtobrutinib 200 mg vs. 120 mg - pirtobrutinib 200 mg vs. 60 mg -
March 25, 2025Pamplona/MadridIn recruitmentEarly phase
-
March 25, 2025Pamplona/MadridIn recruitment
GRWD5769-ST-01 ERAP-1-mediated immunopeptidome-targeted trial
The main objective of this clinical trial is to determine the safety and efficacy of the study drug 12GRWD5769, alone or in combination with another drug called Libtayo® (cemiplimab), against advanced or metastatic malignant solid tumors. -
March 20, 2025Pamplona/MadridIn recruitment
D7630C00001 Datopotamab Deruxtecan (Dato- DXd) trial in patients with inoperable locally recurrent inoperable or metastatic PD-L1-positive triple-negative breast cancer
In this trial, we will compare the investigational treatment with the reference chemotherapy (either paclitaxel, nab-paclitaxel or gemcitabine carboplatin) in combination with pembrolizumab. This trial will also help us to better understand the disease being studied and the health problems associated with it. -
March 13, 2025Pamplona/MadridIn recruitment
C1071006 Trial of elranatamab in participants with newly diagnosed multiple myeloma ineligible for transplantation.
The goal of Part 1 is to find the best dose of elranatamab (also known as PF-06863135) and lenalidomide when given in combination with another drug called daratumumab for use in Part 2 and to learn about the safety and effects of this combination on the body. Elranatamab, daratumumab and lenalidomide are study drugs that are not approved for use in combination. -
March 10, 2025Pamplona/MadridIn recruitmentEarly phase
U31402-A-U102 Multicenter, open-label, phase I clinical trial of U3-1402 in subjects with unresectable or metastatic non-small cell lung cancer.
The purpose of this consent form is to obtain your permission for the release of previously collected tumor tissue (archival tissue) following the growth of your tumor while you were taking your previous cancer medication. -
March 6, 2025Pamplona/MadridIn recruitmentEarly phase
EF-50 Tumor Treatment Clinical Trial (TTFields, 150 kHz) with pembrolizumab for the treatment of metastatic non-small cell lung cancer (NSCLC) previously treated with PD-1/PD-L1 inhibitor and platinum-based chemotherapy
The aim of this study is to evaluate the efficacy and safety of TTFields therapy together with pembrolizumab (a common immunotherapy agent). -
March 5, 2025MadridIn recruitmentEarly phase
222730 Phase I clinical trial to evaluate drug GSK5733584 in participants with advanced solid tumors
The aim of this study is to evaluate the safety, tolerability, pharmacokinetics and anticancer activity of GSK5733584.